Category: InVivo Therapeutics Corp.Syndicate content

InVivo Therapeutics sues ex-CEO Reynolds

March 18, 2014 by Brad Perriello

InVivo Therapeutics says it's suing former CEO Frank Reynolds over $500,000 in allegedly "personal and/or exorbitant expenses."

InVivo Therapeutics sues ex-CEO Reynolds

InVivo Therapeutics (OTC:NVIV) said it's suing former CEO Frank Reynolds, who stepped down last year citing health reasons, alleging that he ran up $500,000 worth of "personal and/or exorbitant expenses."

InVivo issues new protocols for spinal scaffold study

January 7, 2014 by Arezu Sarvestani

Massachusetts-based InVivo Therapeutics awaits final consent after sending new study protocols to FDA regulators and the 6 sites participating in the company's revamped spinal scaffold clinical trial.

InVivo issues new protocols for spinal scaffold study

InVivo lands FDA approval to begin trial of spinal scaffold

January 3, 2014 by Chris Walker

InVivo sets off to launch its 1st investigational clinical trial after landing FDA investigational device exemption for its degradable polymer scaffold for treating spinal cord injury.

InVivo lands FDA conditional approval for clinical trial

InVivo Therapeutics (OTC:NVIV) landed conditional approval from the FDA to change its protocols for its 1st clinical trial, testing its degradable polymer scaffold in treating spinal cord injury.

InVivo names Mark Perrin its new CEO

January 2, 2014 by Chris Walker

InVivo Therapeutics' new CEO Mark Perrin comes from a background in biotech consulting and leadership.

InVivo appoints new CEO

InVivo Therapeutics (OTC:NVIV) named Mark Perrin as its new CEO, handing him the keys to the corner office effective January 6.

The CFO shuffle continues for InVivo Therapeutics | Personnel Moves

December 16, 2013 by Chris Walker

InVivo Therapeutics taps its 3rd CFO since August, naming Steven McAllister to replace interim CFO Gregory Perry.

fired/hired

InVivo Therapeutics (OTC:NVIV) is on its 3rd financial chief since August, saying it named Steven McAllister to replace interim CFO Gregory Perry.

Perry stepped down effective Dec. 30 to join an unnamed biotechnology company as its CFO, according to a press release.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp